Navigation Links
Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors
Date:2/15/2011

SAN DIEGO, Feb. 15, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders (the official journal of the Movement Disorders Society).  The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.  Moreover, it provides the first evidence that neurotrophic factors can improve the status of degenerating dopamine neurons in Parkinson's brains.  New insight important for further improving the bioactivity of NRTN in advanced Parkinson's disease, implemented in the current Phase 2b CERE-120 trial, was also reported.  Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer, who has led the development of CERE-120, is the lead author of the publication.

CERE-120, Ceregene's neurotrophic therapy, currently being clinically tested in advanced Parkinson's disease (PD), is partially funded by the Michael J. Fox Foundation for Parkinson's Research.  CERE-120 is comprised of a viral vector intended to provide constant, sustained expression of neurturin, a neurotrophic factor shown to rescue dying dopaminergic neurons, restoring their function and protecting them from death.  The data in this publication were derived from an analysis of autopsied brain tissue from two patients who were treated in a previous CERE-120 Phase 2 study (see Ceregene press release, May, 2009) and later died of causes unrelated to the treatment.  Ceregene has since confirmed and extended these results by showing persistent, targeted NRTN expression in a patient who had been treated with CERE-120 five years earlier.  

"This new publication provides a stro
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
2. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
5. YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
7. ERT Reports Fourth Quarter and Full Year 2010 Operating Results on March 1, 2011
8. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
9. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
10. Codexis Reports Fourth Quarter and Full Year 2010 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  Atlas Venture, an early ... and technology innovation, today announced that Jason Rhodes ... EPZM ), is joining the firm,s life ... 2014. At Atlas, Rhodes will work closely ... He brings an accomplished record in company creation, deal ...
(Date:9/29/2014)... , September 29, 2014 ... greater competition to transform network connectivity as customers ... ProLabs , the leading independent ... today the findings of their survey conducted at ... with top optical communications professionals from across the ...
(Date:9/29/2014)... 2014 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that the U.S. ... Orphan Drug Designations for the Company,s lead drug ... small cell lung cancer and ovarian cancer.  Aldoxorubicin ... agent, doxorubicin. "The FDA,s decision to ...
(Date:9/28/2014)... Modality Solutions, a ... for highly regulated industries, is pleased to announce ... Advantage Transport Simulation Laboratoryâ„¢ software at the 12th ... Global Forum in Boston, September 29 through October ... lab software on October 2, day two of ...
Breaking Biology Technology:Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3
... , QIAshredder spin columns are designed for simple and rapid homogenization , of cell and ... , , Format: , ... , , Sample source: ... plant cell or tissue lysates, white blood cell lysates, , ...
... , , , , This ... human cancer-related genes for functional genomics research using , RNAi. ... , , , , ... cancer researchers (see table below for a list of genes). Every siRNA has , ...
... Competent Cells for added , convenience, , , , , , , ... Included , Concentration , , , ... , , , ... 50 ng/l, , , Ligation Master ...
Cached Biology Technology:QIAshredder Homogenizer 2Cancer siRNA Oligo Set Version 1.0 2Cancer siRNA Oligo Set Version 1.0 3Cancer siRNA Oligo Set Version 1.0 4
(Date:9/29/2014)... popular culture, mathematics is often deemed inaccessible or esoteric. ... more important role in our daily lives and a ... ideas often behind the scenes. , UC Santa ... Mathematics and an assistant professor of mechanical engineering, often ... of his recent research published in the Proceedings ...
(Date:9/29/2014)... that a combination of a real-time feedback system together ... residence resulted in a reduction of 37% in energy ... 1360.49 kWh, which is equivalent to a reduction of ... , In contrast, another eight halls, exposed only ... resulted in saw a 3.5% reduction in energy consumption. ...
(Date:9/29/2014)... not normally considered capable of doing anything on their ... move through water. In the future, such moving droplets ... your own to be self-moving is a ... entities can be self-moving, report researchers from University of ... Czech Republic. , The researchers have made alcohol droplets ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Scientists make droplets move on their own 2
... Mellon University President Subra Suresh has been elected a ... the only current university president to be elected to ... is among the highest professional distinctions accorded to engineers, ... those who have made outstanding contributions to their fields. ...
... Medicine of the National Academies honored members Donald Berwick, R. ... today at the IOM,s 43rd annual meeting. ... member for distinguished service over an extended period. He ... Care in America, which produced the landmark reports To Err ...
... The Yangtze finless porpoise, which inhabits the high-traffic waters ... endangered, with only about 1,000 animals alive today. Scientists ... colleagues are using medical technology to shed new light ... waterway punctuated by constant shipping, dredging, and underwater construction. ...
Cached Biology News:Carnegie Mellon President Subra Suresh elected to Institute of Medicine 2Institute of Medicine honors members for outstanding service 2Institute of Medicine honors members for outstanding service 3Seeing in the dark 2Seeing in the dark 3
Taq DNA polymerase, 10,000U...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... a versatile and easy-to use enzyme, with ... Taq DNA Polymerase is prepared from a ... the DNA polymerase I gene from Thermococcus ... 5'-3' DNA polymerase activity. Its inherent 3'-5' ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: